CDK2 and breast cancer: To investigate the clinical relevance of activated cyclin E-CDK2 signaling as a resistance biomarker and therapeutic target, we collected 11 pleural effusion samples from HR-positive breast cancer patients and correlated RB and cyclin E expression (Figure 7A) with palbociclib sensitivity (Figure 7B).